<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36736577</PMID><DateCompleted><Year>2023</Year><Month>04</Month><Day>11</Day></DateCompleted><DateRevised><Year>2024</Year><Month>10</Month><Day>01</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1878-3511</ISSN><JournalIssue CitedMedium="Internet"><Volume>130</Volume><PubDate><Year>2023</Year><Month>May</Month></PubDate></JournalIssue><Title>International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases</Title><ISOAbbreviation>Int J Infect Dis</ISOAbbreviation></Journal><ArticleTitle>Systematic review with meta-analysis of active herpesvirus infections in patients with COVID-19: Old players on the new field.</ArticleTitle><Pagination><StartPage>108</StartPage><EndPage>125</EndPage><MedlinePgn>108-125</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.ijid.2023.01.036</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S1201-9712(23)00037-1</ELocationID><Abstract><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">Herpesviruses are ubiquitous and after primary infection they establish lifelong latency. The impairment of maintaining latency with short-term or long-term consequences could be triggered by other infection. Therefore, reactivation of herpesviruses in COVID-19 patients represents an emerging issue.</AbstractText><AbstractText Label="DESIGN AND METHODS" NlmCategory="METHODS">This study provided the first systematic review with meta-analysis of studies that evaluated active human herpesvirus (HHV) infection (defined as the presence of IgM antibodies or HHV-DNA) in COVID-19 patients and included 36 publications collected by searching through PubMed, SCOPUS, and Web of science until November 2022.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The prevalence of active EBV, HHV6, HSV, CMV, HSV1, and VZV infection in COVID-19 population was 41% (95% CI =27%-57%), 3% (95% CI=17%-54%), 28% (95% CI=1%-85%), 25% (95% CI=1%-63%), 22% (95% CI=10%-35%), and 18% (95% CI=4%-34%), respectively. There was a 6 times higher chance for active EBV infection in patients with severe COVID-19 than in non-COVID-19 controls (OR=6.45, 95% CI=1.09-38.13, p=0.040), although there was no difference in the prevalence of all evaluated active herpesvirus infections between COVID-19 patients and non-COVID-19 controls.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Future research of herpesvirus and SARS-CoV-2 coinfections must be prioritized to define: who, when and how to be tested, as well as how to effectively treat HHVs reactivations in acute and long COVID-19 patients.</AbstractText><CopyrightInformation>Copyright &#xa9; 2023 The Author(s). Published by Elsevier Ltd.. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Banko</LastName><ForeName>Ana</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Institute of Microbiology and Immunology, Faculty of Medicine, University of Belgrade, Belgrade, Serbia. Electronic address: ana.banko@med.bg.ac.rs.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Miljanovic</LastName><ForeName>Danijela</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Institute of Microbiology and Immunology, Faculty of Medicine, University of Belgrade, Belgrade, Serbia. Electronic address: danijela.karalic@med.bg.ac.rs.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cirkovic</LastName><ForeName>Andja</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Institute for Medical Statistics and Informatics, Faculty of Medicine, University of Belgrade, Belgrade, Serbia. Electronic address: andja.cirkovic@med.bg.ac.rs.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D017418">Meta-Analysis</PublicationType><PublicationType UI="D000078182">Systematic Review</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>02</Month><Day>01</Day></ArticleDate></Article><MedlineJournalInfo><Country>Canada</Country><MedlineTA>Int J Infect Dis</MedlineTA><NlmUniqueID>9610933</NlmUniqueID><ISSNLinking>1201-9712</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="N">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004854" MajorTopicYN="N">Herpesvirus 4, Human</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003587" MajorTopicYN="N">Cytomegalovirus</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006566" MajorTopicYN="Y">Herpesviridae Infections</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006564" MajorTopicYN="Y">Herpesviridae</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018139" MajorTopicYN="N">Simplexvirus</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015654" MajorTopicYN="Y">Herpesvirus 6, Human</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">CMV</Keyword><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">EBV</Keyword><Keyword MajorTopicYN="N">HSV</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2 infection</Keyword><Keyword MajorTopicYN="N">VZV</Keyword></KeywordList><CoiStatement>Declarations of competing interest The authors have no competing interests to declare.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>11</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>1</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>1</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>4</Month><Day>11</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>2</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>2</Month><Day>3</Day><Hour>19</Hour><Minute>26</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>2</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36736577</ArticleId><ArticleId IdType="pmc">PMC9889115</ArticleId><ArticleId IdType="doi">10.1016/j.ijid.2023.01.036</ArticleId><ArticleId IdType="pii">S1201-9712(23)00037-1</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Connolly SA, Jardetzky TS, Longnecker R. The structural basis of herpesvirus entry. Nat. Rev. Microbiol. 2021;19(2):110&#x2013;121.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8579738</ArticleId><ArticleId IdType="pubmed">33087881</ArticleId></ArticleIdList></Reference><Reference><Citation>Croen KD. Latency of the human herpesviruses. Annu. Rev. Med. 1991;42:61&#x2013;67.</Citation><ArticleIdList><ArticleId IdType="pubmed">1852149</ArticleId></ArticleIdList></Reference><Reference><Citation>Ruiz-Pablos M, Paiva B, Montero-Mateo R, Garcia N, Zabaleta A. Epstein-Barr Virus and the Origin of Myalgic Encephalomyelitis or Chronic Fatigue Syndrome. Front. Immunol. 2021;12</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8634673</ArticleId><ArticleId IdType="pubmed">34867935</ArticleId></ArticleIdList></Reference><Reference><Citation>Shafiee A, Aghajanian S, Athar MMT, Gargari OK. Epstein&#x2013;Barr virus and COVID-19. J. Med. Virol. 2022;94(9):4040&#x2013;4042.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9348397</ArticleId><ArticleId IdType="pubmed">35505635</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith C, Khanna R. Immune regulation of human herpesviruses and its implications for human transplantation. Am. J. Transplant. 2013;13(SUPPL. 3):9&#x2013;23.</Citation><ArticleIdList><ArticleId IdType="pubmed">23347211</ArticleId></ArticleIdList></Reference><Reference><Citation>Proal AD, VanElzakker MB. Long COVID or Post-acute Sequelae of COVID-19 (PASC): An Overview of Biological Factors That May Contribute to Persistent Symptoms. Front. Microbiol. 2021;12</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8260991</ArticleId><ArticleId IdType="pubmed">34248921</ArticleId></ArticleIdList></Reference><Reference><Citation>COVID-19 Data Explorer - Our World in Data [Internet]. [cited 2022 Nov 11];Available from: https://ourworldindata.org/explorers/coronavirus-data-explorer?zoomToSelection=true&amp;country=&#x223c;OWID_WRL&amp;hideControls=true&amp;Interval=New+per+day&amp;Relative+to+Population=false&amp;Metric=Confirmed+cases&amp;Color+by+test+positivity=false.</Citation></Reference><Reference><Citation>Zhou P, Lou Yang X, Wang XG, Hu B, Zhang L, Zhang W, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020;579(7798):270&#x2013;273.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7095418</ArticleId><ArticleId IdType="pubmed">32015507</ArticleId></ArticleIdList></Reference><Reference><Citation>Joshee S, Vatti N, Chang C. Long-Term Effects of COVID-19. Sustain. 2022;97(3):579&#x2013;599.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8752286</ArticleId><ArticleId IdType="pubmed">35246288</ArticleId></ArticleIdList></Reference><Reference><Citation>Galeotti C, Bayry J. Autoimmune and inflammatory diseases following COVID-19. Nat Rev Rheumatol. 2020;16(8):413&#x2013;414.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7271827</ArticleId><ArticleId IdType="pubmed">32499548</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramakrishnan RK, Kashour T, Hamid Q, Halwani R, Tleyjeh IM. Unraveling the Mystery Surrounding Post-Acute Sequelae of COVID-19. Front. Immunol. 2021;12</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8278217</ArticleId><ArticleId IdType="pubmed">34276671</ArticleId></ArticleIdList></Reference><Reference><Citation>Krumbein H, K&#xfc;mmel LS, Fragkou PC, Th&#xf6;lken C, H&#xfc;nerbein BL, Reiter R, et al. Respiratory viral co-infections in patients with COVID-19 and associated outcomes: A systematic review and meta-analysis. Rev. Med. Virol. 2022:e2365.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9347814</ArticleId><ArticleId IdType="pubmed">35686619</ArticleId></ArticleIdList></Reference><Reference><Citation>Davis HE, McCorkell L, Vogel JM, Topol EJ. Long COVID: major findings, mechanisms and recommendations. Nat. Rev. Microbiol. 2023:1&#x2013;14.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9839201</ArticleId><ArticleId IdType="pubmed">36639608</ArticleId></ArticleIdList></Reference><Reference><Citation>Malekifar P, Pakzad R, Shahbahrami R, Zandi M, Jafarpour A, Rezayat SA, et al. Viral Coinfection among COVID-19 Patient Groups: An Update Systematic Review and Meta-Analysis. Biomed Res. Int. 2021</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8416381</ArticleId><ArticleId IdType="pubmed">34485513</ArticleId></ArticleIdList></Reference><Reference><Citation>Pakzad R, Malekifar P, Shateri Z, Zandi M, Akhavan Rezayat S, Soleymani M, et al. Worldwide prevalence of microbial agents&#x2019; coinfection among COVID-19 patients: A comprehensive updated systematic review and meta-analysis. J. Clin. Lab. Anal. 2022;36(1)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8761407</ArticleId><ArticleId IdType="pubmed">34851526</ArticleId></ArticleIdList></Reference><Reference><Citation>Liberati A, Altman DG, Tetzlaff J, Mulrow C, G&#xf8;tzsche PC, Ioannidis JPA, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: Explanation and elaboration. PLoS Med. 2009;6(7)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2707010</ArticleId><ArticleId IdType="pubmed">19621070</ArticleId></ArticleIdList></Reference><Reference><Citation>Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D, et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA. 2000;283(15):2008&#x2013;2012.</Citation><ArticleIdList><ArticleId IdType="pubmed">10789670</ArticleId></ArticleIdList></Reference><Reference><Citation>Higgins J.P., Thomas J., Chandler J., Cumpston M., Li T., Page M.J., Welch VA. John Wiley &amp; Sons; 2019. Cochrane handbook for systematic reviews of interventions.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10284251</ArticleId><ArticleId IdType="pubmed">31643080</ArticleId></ArticleIdList></Reference><Reference><Citation>Wells G, Shea B, O'connell D, Peterson J W V. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. 2014;</Citation></Reference><Reference><Citation>Jadad AR, Andrew Moore R, Carroll D, Jenkinson C, John Reynolds DM, Gavaghan DJ, et al. Assessing the Quality of Reports of Randomized Clinical Trials: Is Blinding Necessary? Control. Clin Trials. 1996;17:1&#x2013;12.</Citation><ArticleIdList><ArticleId IdType="pubmed">8721797</ArticleId></ArticleIdList></Reference><Reference><Citation>RevMan | Cochrane Training.</Citation></Reference><Reference><Citation>Abad&#xed;as-Granado I, Navarro-Bielsa A, Morales-Callaghan AM, Roc L, Suso-Est&#xed;valez CC, Povar-Echeverr&#xed;a M, et al. COVID-19-associated cutaneous manifestations: does human herpesvirus 6 play an aetiological role? Br. J. Dermatol. 2021;184(6):1187&#x2013;1190.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8014469</ArticleId><ArticleId IdType="pubmed">33420720</ArticleId></ArticleIdList></Reference><Reference><Citation>Arag&#xf3;n-Nogales R, Zurita-Cruz J, V&#xe1;zquez-Rosales G, Arias-Flores R, G&#xf3;mez-Gonz&#xe1;lez C, Monta&#xf1;o-Luna V, et al. Clinical presentation of pediatric patients with symptomatic SARS-CoV-2 infection during the first months of the COVID-19 pandemic in a single center in Mexico City. Front. Pediatr. 2022;10</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9366046</ArticleId><ArticleId IdType="pubmed">35967584</ArticleId></ArticleIdList></Reference><Reference><Citation>Basic-Jukic N, Juric I, Furic-Cunko V, Katalinic L, Radic J, Bosnjak Z, et al. Follow-up of renal transplant recipients after acute COVID-19&#x2014;A prospective cohort single-center study. Immunity, Inflamm. Dis. 2021;9(4):1563&#x2013;1572.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8426882</ArticleId><ArticleId IdType="pubmed">34414665</ArticleId></ArticleIdList></Reference><Reference><Citation>Blumenthal MJ, Lambarey H, Chetram A, Riou C, Wilkinson RJ, Sch&#xe4;fer G. Kaposi's Sarcoma-Associated Herpesvirus, but Not Epstein-Barr Virus, Co-infection Associates With Coronavirus Disease 2019 Severity and Outcome in South African Patients. Front. Microbiol. 2022;12</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8770866</ArticleId><ArticleId IdType="pubmed">35069495</ArticleId></ArticleIdList></Reference><Reference><Citation>Brinkmann A, Uddin S, Ulm SL, Pape K, F&#xf6;rster S, Enan K, et al. RespiCoV: Simultaneous identification of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and 46 respiratory tract viruses and bacteria by amplicon-based Oxford-Nanopore MinION sequencing. PLoS One. 2022;17(3)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8906600</ArticleId><ArticleId IdType="pubmed">35263362</ArticleId></ArticleIdList></Reference><Reference><Citation>Brooks B, Tancredi C, Song Y, Mogus AT, Huang MLW, Zhu H, et al. Epstein&#x2013;Barr Virus and Human Herpesvirus-6 Reactivation in Acute COVID-19 Patients. Viruses. 2022;14(9):1872.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9504756</ArticleId><ArticleId IdType="pubmed">36146679</ArticleId></ArticleIdList></Reference><Reference><Citation>Busani S, Tosi M, Mighali P, Vandelli P, D'Amico R, Marietta M, et al. Multi-centre, three arm, randomized controlled trial on the use of methylprednisolone and unfractionated heparin in critically ill ventilated patients with pneumonia from SARS-CoV-2 infection: A structured summary of a study protocol for a randomised cont. Trials. 2020;21:724.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7429933</ArticleId><ArticleId IdType="pubmed">32807241</ArticleId></ArticleIdList></Reference><Reference><Citation>Carneiro VC de S, Alves-Leon SV, Sarmento DJ de S, Coelho WL da CNP, Moreira O da C, Salvio AL, et al. Herpesvirus and neurological manifestations in patients with severe coronavirus disease. Virol. J. 2022;19(1):1&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9174631</ArticleId><ArticleId IdType="pubmed">35676707</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen T, Song J, Liu H, Zheng H, Chen C. Positive Epstein&#x2013;Barr virus detection in coronavirus disease 2019 (COVID-19) patients. Sci. Rep. 2021;11:10902.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8149409</ArticleId><ArticleId IdType="pubmed">34035353</ArticleId></ArticleIdList></Reference><Reference><Citation>Gatto I, Biagioni E, Coloretti I, Farinelli C, Avoni C, Caciagli V, et al. Cytomegalovirus blood reactivation in COVID-19 critically ill patients: risk factors and impact on mortality. Intensive Care Med. 2022;48(6):706&#x2013;713.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9116062</ArticleId><ArticleId IdType="pubmed">35583676</ArticleId></ArticleIdList></Reference><Reference><Citation>Gold JE, Okyay RA, Licht WE, Hurley DJ. Investigation of long covid prevalence and its relationship to epstein-barr virus reactivation. Pathogens. 2021;10:763.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8233978</ArticleId><ArticleId IdType="pubmed">34204243</ArticleId></ArticleIdList></Reference><Reference><Citation>Halawi M, Al-Hazmi A, Aljuaid A, Allahyani M, Abdulaziz O, Almalki AA, et al. Seroprevalence of toxoplasma gondii, rubella, group a streptococcus, cmv and hsv-1 in covid-19 patients with vitamin d deficiency. Pakistan J. Biol. Sci. 2021;24(11):1169&#x2013;1174.</Citation><ArticleIdList><ArticleId IdType="pubmed">34842389</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang R-C, Chiu C-H, Chiang T-T, Tsai C-C, Wang Y-C, Chang F-Y, et al. Hospital-acquired infections in patients hospitalized with COVID-19: First report from Taiwan. J. Chinese Med. Assoc. 2022;85(9):922&#x2013;927.</Citation><ArticleIdList><ArticleId IdType="pubmed">35727096</ArticleId></ArticleIdList></Reference><Reference><Citation>Im JH, Nahm CH, Je YS, Lee J-S, Baek JH, Kwon HY, et al. The effect of Epstein&#x2013;Barr virus viremia on the progression to severe COVID-19. Medicine (Baltimore) 2022;101(18):e29027.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9276369</ArticleId><ArticleId IdType="pubmed">35550458</ArticleId></ArticleIdList></Reference><Reference><Citation>Kahwagi J, Seye AO, Mbodji AB, Diagne R, Mbengue E, Fall M, et al. Surveillance of Viral Encephalitis in the Context of COVID-19&#x202f;: Viruses. 2022;14:871.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9145710</ArticleId><ArticleId IdType="pubmed">35632613</ArticleId></ArticleIdList></Reference><Reference><Citation>Katz J, Yue S, Xue W. Herpes simplex and herpes zoster viruses in COVID-19 patients. Ir. J. Med. Sci. 2022;191(3):1093&#x2013;1097.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8272836</ArticleId><ArticleId IdType="pubmed">34247308</ArticleId></ArticleIdList></Reference><Reference><Citation>Lehner GF, Klein SJ, Zoller H, Peer A, Bellmann R, Joannidis M. Correlation of interleukin-6 with Epstein&#x2013;Barr virus levels in COVID-19. Crit. Care. 2020;24:657.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7682685</ArticleId><ArticleId IdType="pubmed">33228750</ArticleId></ArticleIdList></Reference><Reference><Citation>Lino K, Alves LS, Raposo J V, Medeiros T, Souza CF, Silva AA d, et al. Presence and clinical impact of human herpesvirus-6 infection in patients with moderate to critical coronavirus disease-19. J. Med. Virol. 2022;94(3):1212&#x2013;1216.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8662171</ArticleId><ArticleId IdType="pubmed">34647632</ArticleId></ArticleIdList></Reference><Reference><Citation>Majtanova N, Kriskova P, Keri P, Fellner Z, Majtan J, Kolar P. Herpes simplex keratitis in patients with SARS-CoV-2 infection: A series of five cases. Med. 2021;57:412.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8146587</ArticleId><ArticleId IdType="pubmed">33923158</ArticleId></ArticleIdList></Reference><Reference><Citation>Meng M, Zhang S, Dong X, Sun W, Deng Y, Li W, et al. COVID-19 associated EBV reactivation and effects of ganciclovir treatment. Immunity, Inflamm. Dis. 2022;10(4):e597.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8959425</ArticleId><ArticleId IdType="pubmed">35349757</ArticleId></ArticleIdList></Reference><Reference><Citation>Meyer A, Buetti N, Houhou-Fidouh N, Patrier J, Abdel-Nabey M, Jaquet P, et al. HSV-1 reactivation is associated with an increased risk of mortality and pneumonia in critically ill COVID-19 patients. Crit. Care. 2021;25:417.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8647503</ArticleId><ArticleId IdType="pubmed">34872611</ArticleId></ArticleIdList></Reference><Reference><Citation>Naendrup JH, Borrega Jorge G, Dennis Alexander E, Alexander SV, Matthias K, Boris B. Reactivation of EBV and CMV in Severe COVID-19&#x2014;Epiphenomena or Trigger of Hyperinflammation in Need of Treatment? A Large Case Series of Critically ill Patients. J. Intensive Care Med. 2021;18</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9396115</ArticleId><ArticleId IdType="pubmed">34791940</ArticleId></ArticleIdList></Reference><Reference><Citation>Paolucci S, Cassaniti I, Novazzi F, Fiorina L, Piralla A, Comolli G, et al. EBV DNA increase in COVID-19 patients with impaired lymphocyte subpopulation count. Int J Infect Dis. 2021;104:315&#x2013;319.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7833117</ArticleId><ArticleId IdType="pubmed">33359064</ArticleId></ArticleIdList></Reference><Reference><Citation>Romani L, Del Chierico F, Macari G, Pane S, Ristori MV, Guarrasi V, et al. The Relationship Between Pediatric Gut Microbiota and SARS-CoV-2 Infection. Front. Cell. Infect. Microbiol. 2022;12</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9304937</ArticleId><ArticleId IdType="pubmed">35873161</ArticleId></ArticleIdList></Reference><Reference><Citation>Saade A, Moratelli G, Azoulay E, Darmon M. Herpesvirus reactivation during severe COVID-19 and high rate of immune defect. Infect. Dis. Now. 2021;51(8):676&#x2013;679.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8317452</ArticleId><ArticleId IdType="pubmed">34332165</ArticleId></ArticleIdList></Reference><Reference><Citation>See&#xdf;le J, Hippchen T, Schnitzler P, Gsenger J, Giese T, Merle U. High rate of HSV-1 reactivation in invasively ventilated COVID-19 patients: Immunological findings. PLoS One. 2021;16(7)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8248692</ArticleId><ArticleId IdType="pubmed">34197543</ArticleId></ArticleIdList></Reference><Reference><Citation>Simonnet A, Engelmann I, Moreau A, Garcia B, Six S, Kalioubie A El. High incidence of Epstein&#x2013;Barr virus, cytomegalovirus, and human-herpes virus-6 reactivations in critically ill patients with COVID-19. Infect Dis Now. 2021;51(1):296&#x2013;299.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7816954</ArticleId><ArticleId IdType="pubmed">33495765</ArticleId></ArticleIdList></Reference><Reference><Citation>Singh V, Upadhyay P, Reddy J, Granger J. SARS-CoV-2 respiratory co-infections: Incidence of viral and bacterial co-pathogens. Int. J. Infect. Dis. 2021;105:617&#x2013;620.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7905386</ArticleId><ArticleId IdType="pubmed">33640570</ArticleId></ArticleIdList></Reference><Reference><Citation>Su Y, Yuan D, Chen DG, Ng RH, Wang K, Choi J, et al. Multiple early factors anticipate post-acute COVID-19 sequelae. Cell. 2022;185(5):881&#x2013;895. e20.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8786632</ArticleId><ArticleId IdType="pubmed">35216672</ArticleId></ArticleIdList></Reference><Reference><Citation>Vig&#xf3;n L, Garc&#xed;a-P&#xe9;rez J, Rodr&#xed;guez-Mora S, Torres M, Mateos E, Castillo de la Osa M, et al. Impaired Antibody-Dependent Cellular Cytotoxicity in a Spanish Cohort of Patients With COVID-19 Admitted to the ICU. Front. Immunol. 2021;12</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8488389</ArticleId><ArticleId IdType="pubmed">34616404</ArticleId></ArticleIdList></Reference><Reference><Citation>Wenzel P, Kopp S, Gobel S, Jansen T, Geyer M, Hahn F, et al. Evidence of SARS-CoV-2 mRNA in endomyocardial biopsies of patients with clinically suspected myocarditis tested negative for COVID-19 in nasopharyngeal swab. Cardiovasc. Res. 2020 Aug 1;116(10):1661&#x2013;1663.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7337685</ArticleId><ArticleId IdType="pubmed">32562489</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu Q, Xing Y, Shi L, Li W, Gao Y, Pan S, et al. Coinfection and other clinical characteristics of COVID-19 in children. Pediatrics. 2020;146(1)</Citation><ArticleIdList><ArticleId IdType="pubmed">32376725</ArticleId></ArticleIdList></Reference><Reference><Citation>Xie Y, Cao S, Dong H, Lv H, Teng X, Zhang J, et al. Clinical characteristics and outcomes of critically ill patients with acute COVID-19 with Epstein-Barr virus reactivation. BMC Infect. Dis. 2021;21:955.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8441951</ArticleId><ArticleId IdType="pubmed">34525962</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao Y, Wang F, Dong G, Sheng Q, Feng S. A disease progression prediction model and nervous system symptoms in coronavirus disease 2019 patients. Am. J. Transl. Res. 2021;12(12):8192&#x2013;8207.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7791519</ArticleId><ArticleId IdType="pubmed">33437392</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu J, Wu Y. COVID-19 Epidemic: Clinical Characteristics of Patients in Pediatric Isolation Ward. Clin. Pediatr. (Phila). 2020;59(12):1069&#x2013;1073.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7430102</ArticleId><ArticleId IdType="pubmed">32646234</ArticleId></ArticleIdList></Reference><Reference><Citation>Zubchenko S, Kril I, Nadizhko O, Matsyura O, Chopyak V. Herpesvirus infections and post-COVID-19 manifestations: a pilot observational study. Rheumatol. Int. 2022;42(9):1523&#x2013;1530.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9159383</ArticleId><ArticleId IdType="pubmed">35650445</ArticleId></ArticleIdList></Reference><Reference><Citation>Phetsouphanh C, Darley DR, Wilson DB, Howe A, Munier CML, Patel SK, et al. Immunological dysfunction persists for 8 months following initial mild-to-moderate SARS-CoV-2 infection. Nat. Immunol. 2022;23(2):210&#x2013;216.</Citation><ArticleIdList><ArticleId IdType="pubmed">35027728</ArticleId></ArticleIdList></Reference><Reference><Citation>Proal A, Marshall T. Myalgic encephalomyelitis/chronic fatigue syndrome in the era of the human microbiome: Persistent pathogens drive chronic symptoms by interfering with host metabolism, gene expression, and immunity. Front. Pediatr. 2018;6:373.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6288442</ArticleId><ArticleId IdType="pubmed">30564562</ArticleId></ArticleIdList></Reference><Reference><Citation>Barton LM, Duval EJ, Stroberg E, Ghosh S, Mukhopadhyay S. COVID-19 autopsies, Oklahoma, USA. Am. J. Clin. Pathol. 2020;153(6):725&#x2013;733.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7184436</ArticleId><ArticleId IdType="pubmed">32275742</ArticleId></ArticleIdList></Reference><Reference><Citation>Taefehshokr N, Taefehshokr S, Hemmat N, Heit B. Covid-19: Perspectives on Innate Immune Evasion. Front. Immunol. 2020;11</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7554241</ArticleId><ArticleId IdType="pubmed">33101306</ArticleId></ArticleIdList></Reference><Reference><Citation>Sa Ribero M, Jouvenet N, Dreux M, Nisole S. Interplay between SARS-CoV-2 and the type I interferon response. PLoS Pathog. 2020;16(7)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7390284</ArticleId><ArticleId IdType="pubmed">32726355</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen L, Quach T. COVID-19 cytokine storm syndrome: a threshold concept. Lancet Microbe. 2021;2(2):e49&#x2013;e50.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7906728</ArticleId><ArticleId IdType="pubmed">33655230</ArticleId></ArticleIdList></Reference><Reference><Citation>Le-Trilling VTK, Trilling M. Attack, parry and riposte: Molecular fencing between the innate immune system and human herpesviruses. Tissue Antigens. 2015;86(1):1&#x2013;13.</Citation><ArticleIdList><ArticleId IdType="pubmed">26061653</ArticleId></ArticleIdList></Reference><Reference><Citation>Acharya D, Liu GQ, Gack MU. Dysregulation of type I interferon responses in COVID-19. Nat. Rev. Immunol. 2020;20(7):397&#x2013;398.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7249038</ArticleId><ArticleId IdType="pubmed">32457522</ArticleId></ArticleIdList></Reference><Reference><Citation>Zheng M, Gao Y, Wang G, Song G, Liu S, Sun D, et al. Functional exhaustion of antiviral lymphocytes in COVID-19 patients. Cell. Mol. Immunol. 2020;17(5):533&#x2013;535.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7091858</ArticleId><ArticleId IdType="pubmed">32203188</ArticleId></ArticleIdList></Reference><Reference><Citation>D'souza S, Lau KCK, Coffin CS, Patel TR. Molecular mechanisms of viral hepatitis induced hepatocellular carcinoma. World J. Gastroenterol. 2020;26(38):5759&#x2013;5783.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7579760</ArticleId><ArticleId IdType="pubmed">33132633</ArticleId></ArticleIdList></Reference><Reference><Citation>Aghbash PS, Eslami N, Shirvaliloo M, Baghi HB. Viral coinfections in COVID-19. J. Med. Virol. 2021;93(9):5310&#x2013;5322.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8242380</ArticleId><ArticleId IdType="pubmed">34032294</ArticleId></ArticleIdList></Reference><Reference><Citation>Cardozo CM, Hainaut P. Viral strategies for circumventing p53: The case of severe acute respiratory syndrome coronavirus. Curr. Opin. Oncol. 2021;33(2):149&#x2013;158.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7924916</ArticleId><ArticleId IdType="pubmed">33405482</ArticleId></ArticleIdList></Reference><Reference><Citation>Nunn AVW, Guy GW, Botchway SW, Bell JD. SARS-CoV-2 and EBV; the cost of a second mitochondrial &#x201c;whammy&#x201d;? Immun. Ageing. 2021;18(1):40.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8556816</ArticleId><ArticleId IdType="pubmed">34717676</ArticleId></ArticleIdList></Reference><Reference><Citation>Galv&#xe1;n Casas C, Catal&#xe0; A, Carretero Hern&#xe1;ndez G, Rodr&#xed;guez-Jim&#xe9;nez P, Fern&#xe1;ndez-Nieto D, Rodr&#xed;guez-Villa Lario A, et al. Classification of the cutaneous manifestations of COVID-19: a rapid prospective nationwide consensus study in Spain with 375 cases. Br. J. Dermatol. 2020;183(1):71&#x2013;77.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7267236</ArticleId><ArticleId IdType="pubmed">32348545</ArticleId></ArticleIdList></Reference><Reference><Citation>Dursun R, Temiz SA. The clinics of HHV-6 infection in COVID-19 pandemic: Pityriasis rosea and Kawasaki disease. Dermatol. Ther. 2020;33(4):2019&#x2013;2021.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7300497</ArticleId><ArticleId IdType="pubmed">32475003</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y, Wang D, Tao X. Human herpesvirus 6B encephalitis in a liver transplant recipient: A case report and review of the literature. Transpl. Infect. Dis. 2021;23(1):1&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7988578</ArticleId><ArticleId IdType="pubmed">32638491</ArticleId></ArticleIdList></Reference><Reference><Citation>Costa BK da, Sato DK. Viral encephalitis: a practical review on diagnostic approach and treatment. J. Pediatr. (Rio. J). 2020;96(S1):12&#x2013;19.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9431993</ArticleId><ArticleId IdType="pubmed">31513761</ArticleId></ArticleIdList></Reference><Reference><Citation>Chapenko S, Krumina A, Logina I, Rasa S, Chistjakovs M, Sultanova A, et al. Association of active human herpesvirus-6, -7 and parvovirus B19 infection with clinical outcomes in patients with myalgic encephalomyelitis/chronic fatigue syndrome. Adv. Virol. 2012;2012</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3426163</ArticleId><ArticleId IdType="pubmed">22927850</ArticleId></ArticleIdList></Reference><Reference><Citation>Ariza ME. Myalgic encephalomyelitis/chronic fatigue syndrome: The human herpesviruses are back! Biomolecules. 2021;11(2):185.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7912523</ArticleId><ArticleId IdType="pubmed">33572802</ArticleId></ArticleIdList></Reference><Reference><Citation>Kadambari S, Klenerman P, Pollard AJ. Why the elderly appear to be more severely affected by COVID-19: The potential role of immunosenescence and CMV. Rev. Med. Virol. 2020;30(5):1&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7404358</ArticleId><ArticleId IdType="pubmed">32671966</ArticleId></ArticleIdList></Reference><Reference><Citation>Juric I, Katalinic L, Furic-Cunko V, Basic-Jukic N. Myelodysplastic syndrome in a kidney transplant recipient after SARS-CoV-2 infection: can SARS-CoV-2 induce myelodysplastic syndrome? Int. Urol. Nephrol. 2022;54(7):1775&#x2013;1776.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8609253</ArticleId><ArticleId IdType="pubmed">34813025</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu R, Zhou Y, Cai L, Wang L, Han J, Yang X, et al. Co-reactivation of the human herpesvirus alpha subfamily (herpes simplex virus-1 and varicella zoster virus) in a critically ill patient with COVID-19. Br. J. Dermatol. 2020;183(6):1145&#x2013;1147.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7436688</ArticleId><ArticleId IdType="pubmed">32790074</ArticleId></ArticleIdList></Reference><Reference><Citation>Diez-Domingo J, Parikh R, Bhavsar AB, Cisneros E, McCormick N, Lecrenier N. Can COVID-19 Increase the Risk of Herpes Zoster? A Narrative Review. Dermatol. Ther. (Heidelb). 2021;11(4):1119&#x2013;1126.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8126597</ArticleId><ArticleId IdType="pubmed">33999370</ArticleId></ArticleIdList></Reference><Reference><Citation>Readhead B, Haure-Mirande J, Funk C, Richards M, Shannon P, Haroutunian V, et al. Multiscale analysis of three independent Alzheimer's cohorts reveals disruption of molecular, genetic, and clinical networks by Human herpesvirus. Physiol. Behav. 2017;176(3):139&#x2013;148.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6551233</ArticleId><ArticleId IdType="pubmed">29937276</ArticleId></ArticleIdList></Reference><Reference><Citation>Magri F, Giordano S, Latini A, Muscianese M. New-onset cutaneous kaposi's sarcoma following SARS-CoV-2 infection. J. Cosmet. Dermatol. 2021;20(12):3747&#x2013;3750.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8661758</ArticleId><ArticleId IdType="pubmed">34731523</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>